RankingsPricing
  1. US-listed companies
  2. LIGAND PHARMACEUTICALS INC
  3. Financials
  4. Diluted EPS

LIGAND PHARMACEUTICALS INC【LGND】

Market cap
$3.9B
P/E ratio
SummaryFinancials
Period EndDiluted EPS (USD)YoY (%)
Dec 31, 2024-0.2-107.48%
Dec 31, 20232.9-248.48%
Dec 31, 2022-2-159.82%
Dec 31, 20213.3-1938.89%
Dec 31, 2020-0.2-100.57%
Dec 31, 201931.9+434.40%
Dec 31, 20186+1024.53%
Dec 31, 20170.5-762.50%
Dec 31, 2016-0.1-100.66%
Dec 31, 201512.1+2064.29%
Dec 31, 20140.6+1.82%
Dec 31, 20130.6

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)